Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

PDF  |  How to cite

Oncotarget. 2022; 13:982-982. https://doi.org/10.18632/oncotarget.28262

Metrics: PDF 525 views  |   ?  

Sewanti Limaye1, Prashant Kumar2,3,4, Ramya Pragya1, Janani Sambath3,4, Darshana Patil2, Ajay Srinivasan2, Sachin Apurva2, Navin Srivastava2, Sanket Patil2, Revati Patil2, Vineet Datta2, Dadasaheb Akolkar2 and Rajan Datar2

1Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
2Datar Cancer Genetics Limited, Nasik, Maharashtra, India
3Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India
4Manipal Academy of Higher Education, Manipal, Karnataka, India

Published: August 04, 2022

Copyright: © 2022 Limaye et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The patient provided consent (by signing on a consent document) at the time of tumor tissue and blood sample collection stating willingness to:

  1. Provide the required sample for tumor molecular profiling.
  2. Research use of deidentified data including publication of (deidentified) findings.

Original article: Oncotarget. 2020; 11:4358–4363. DOI: https://doi.org/10.18632/oncotarget.27809

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28262